美国食品和药物管理局(FDA)于当地时间11月9日发布药物安全公告,指出使用GLP-1受体激动剂类药物可能增加患“非动脉炎性前部缺血性视神经病变”(NAION)的风险,该罕见眼病可能导致永久视力丧失 1。此次公告涉及的主要药物包括司美格鲁肽和替尔泊肽,对应的制药企业为诺和诺德与礼来 1。根据2025年的数据,诺和诺德的司美格鲁肽全球销售额约为361亿美元,而礼来的替尔泊肽全球销售额约为365.07亿美元 1。
针对这一风险警告,FDA要求相关药物的上市申请持有者在药品说明书的“警告与注意事项”部分增加此类风险信息 1。诺和诺德随后发表声明称,现有研究并未证实GLP-1药物会导致NAION,公司认为目前的数据没有建立起因果关系 1。礼来方面则回应表示,FDA的通告适用于所有GLP-1药物,并非针对该公司的特定发现,目前正在认真评估这一监管通告 1。此外,自2025年以来已有律所代表患者向法院提起了90多起相关诉讼 1。
The U.S. Food and Drug Administration (FDA) issued a drug safety communication on November 9 stating that GLP-1 receptor agonists, including semaglutide and tirzepatide, may increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can lead to permanent vision loss 1. In response to these findings, the agency has required marketing authorization holders to include this potential risk in the "Warnings and Precautions" section of their product labeling 1. The announcement immediately drew significant public attention, with keywords regarding side effects trending online, involving major pharmaceutical companies Novo Nordisk and Eli Lilly 1.
Novo Nordisk stated that existing studies have not confirmed that GLP-1 medications cause NAION, asserting that current data does not establish a causal relationship 1. Meanwhile, Eli Lilly responded that the FDA notice applies to all GLP-1 drugs rather than being specific to their own findings, adding that the company is carefully evaluating the regulatory communication 1. Since 2025, more than 90 lawsuits have been filed by patients against manufacturers through law firms 1. Financially, the impact is substantial for both companies; in 2025, global sales for Novo Nordisk’s semaglutide reached approximately $36.1 billion, while Eli Lilly’s tirzepatide generated about $36.507 billion 1.
评论
还没有评论,欢迎留下第一条。